

STIC-EIC1600/2900

286178

From: SHOBHA KANTAMNENI [shobha.kantamneni@uspto.gov]**Sent:** Tuesday, February 17, 2009 9:06 AM**To:** STIC-EIC1600/2900**Subject:** Search Request, Case/Application No.: 10590575**Requester:** SHOBHA KANTAMNENI (P/1617)**Art Unit:** GROUP ART UNIT 1617**Employee Number:****Office Location:** REM 4A5**Phone Number:** (571)272-2930**Case/Application number:** 10590575**Priority Filing Date:****Format for Search Results:** No selection**Meaning of unusual acronyms or initialisms:**

Identify the novelty:

Additional comments:

Please, do structure search for compounds of formula as in claim 28. Please, include all the compounds as in claims 32-37. See attached claims.

Attachment: Yes (590575, Claims, Whole Document.pdf)

2/17/2009

LB


=> d ibib abs hitstr 16 1-2

L6 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:733706 HCAPLUS Full-text
 DOCUMENT NUMBER: 147:110212
 TITLE: Methods for treating cutaneous lupus using
 aminoisoindoline compounds
 INVENTOR(S): Zeldis, Jerome B.; Rohane, Patricia E. W.;
 Schafer, Peter H.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 27pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070155791	A1	20070705	US 2006-645319	20061221
AU 2006332677	A1	20070712	AU 2006-332677	20061228
CA 2635252	A1	20070712	CA 2006-2635252	20061228
WO 2007079182	A1	20070712	WO 2006-US49490	20061228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1965793	A1	20080910	EP 2006-848280	20061228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
KR 2008086527	A	20080925	KR 2008-718496	20080728
PRIORITY APPLN. INFO.:				
			US 2005-754795P	P 20051229
			US 2005-755246P	P 20051229
			US 2006-787436P	P 20060330
			WO 2006-US49490	W 20061228
AB Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonyl]ethyl]-4- acetylaminisoindoline-1,3-dione, 4-(amino)-2-[2,6-dioxo(3-piperidyl)]- isoindoline-1,3-dione (ACTIMID), 3-(4-amino-1-oxo-1,3-dihydroisoindol-2- yl)-piperidine-2,6-dione (REVLIMID), or cyclopropyl 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3- oxoisoindolin-4-yl carboxamide, alone or alternatively, in combination with a second active agent. Compound preparation is included.				
IT 19171-19-8 39746-25-3, 16,16-Dimethyl-PGE2				
191732-72-6 202271-89-4 202271-90-7				
202271-91-8 340019-69-4 608141-41-9				
874946-00-6				
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(aminoisoindoline compds. for treatment of cutaneous lupus)				

RN 19171-19-8 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 4-amino-2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)




RN 39746-25-3 HCAPLUS

CN Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, (5Z,11α,13E,15R)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



RN 191732-72-6 HCAPLUS


CN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)- (CA INDEX NAME)



RN 202271-89-4 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 4-amino-2-[(3S)-2,6-dioxo-3-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 202271-90-7 HCAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 4-amino-2-[(3R)-2,6-dioxo-3-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 202271-91-8 HCAPLUS

CN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 340019-69-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-3-oxo-1H-isoindol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 608141-41-9 HCAPLUS

CN Acetamide, N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 874946-00-6 HCAPLUS

CN 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-,
(3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 603-11-2, 3-Nitrophthalic acid 1188-21-2,
N-Acetyl-L-leucine 4023-34-1, Cyclopropanecarbonyl
chloride 253168-94-4 635705-76-9 943225-74-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(aminoisoindoline compds. for treatment of cutaneous lupus)

RN 603-11-2 HCAPLUS


CN 1,2-Benzenedicarboxylic acid, 3-nitro- (CA INDEX NAME)



RN 1188-21-2 HCAPLUS

CN L-Leucine, N-acetyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 4023-34-1 HCAPLUS

CN Cyclopropanecarbonyl chloride (CA INDEX NAME)



RN 253168-94-4 HCAPLUS


CN Benzenemethanamine, 3-ethoxy-4-methoxy- α -[(methylsulfonyl)methyl]-
(CA INDEX NAME)



RN 635705-76-9 HCAPLUS

CN 1H-Isindol-1-one, 7-amino-2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 943225-74-9 HCAPLUS

CN Benzoic acid, 2-amino-6-[[[(1S)-4-amino-1-carboxy-4-oxobutyl]amino]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 108-24-7P, Acetic anhydride 5434-20-8P, 3-Aminophthalic acid 6296-53-3P, 3-Acetamidophthalic anhydride 608141-43-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aminoisindoline compds. for treatment of cutaneous lupus)

RN 108-24-7 HCAPLUS

CN Acetic acid, 1,1'-anhydride (CA INDEX NAME)



RN 5434-20-8 HCAPLUS

CN 1,2-Benzenedicarboxylic acid, 3-amino- (CA INDEX NAME)



RN 6296-53-3 HCAPLUS

CN Acetamide, N-(1,3-dihydro-1,3-dioxo-4-isobenzofuranyl)- (CA INDEX NAME)



RN 608141-43-1 HCAPLUS


CN L-Leucine, N-acetyl-, compd. with (αS)-3-ethoxy-4-methoxy-α-[(methylsulfonyl)methyl]benzenemethanamine (1:1) (CA INDEX NAME)

CM 1

CRN 608141-42-0

CMF C12 H19 N O4 S

Absolute stereochemistry.



CM 2

CRN 1188-21-2


CMF C8 H15 N O3

Absolute stereochemistry. Rotation (-).



IT 363-24-6, PGE2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (combination; aminoisindoline compds. for treatment of cutaneous
 lupus)
 RN 363-24-6 HCAPLUS
 CN Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-,
 (5Z,11α,13E,15S)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L6 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:1256700 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 146:811
 TITLE: Methods and compositions using 4-[(
 cyclopropanecarbonylamino
)methyl]-2-(2,6-dioxopiperidin-3-yl)isindole-1,3-
 dione for the treatment or prevention of cutaneous
 lupus
 INVENTOR(S): Zeldis, Jerome B.; Rohane, Patricia E. W.;
 Schafer, Peter H.
 PATENT ASSIGNEE(S): Celgene Corporation, USA
 SOURCE: PCT Int. Appl., 46pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006127938	A1	20061130	WO 2006-US20311	20060523
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,			

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

US 20060270707	A1	20061130	US 2006-435089	20060516
CA 2608220	A1	20061130	CA 2006-2608220	20060523
EP 1896024	A1	20080312	EP 2006-771221	20060523

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU

JP 2008542290	T	20081127	JP 2008-513723	20060523
---------------	---	----------	----------------	----------


PRIORITY APPLN. INFO.: US 2005-68499P P 20050524
 WO 2006-US20311 W 20060523

AB Methods of treating, managing, or preventing cutaneous lupus are disclosed. Specific methods encompass the administration of 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione (preparation of the HCl salt is described), alone or in combination with a second active agent. Pharmaceutical compns. and single unit dosage forms are also disclosed.

IT 50-18-0, Cyclophosphamide 50-35-1, Thalidomide
 57-92-1, Streptomycin 59-05-2, Methotrexate
 60-54-8, Tetracycline 69-53-4, Ampicillin
 69-72-7D, Salicylic acid, salicylates, biological studies
 89-57-6D, 5-Aminosalicylic acid, derivs. 103-90-2,
 Acetaminophen 114-07-8, Erythromycin 446-86-6,
 Azathioprine 768-94-5, Amantadine 1406-05-9,
 Penicillin 8063-07-8, Kanamycin 11111-12-9,
 Cephalosporin 13392-28-4, Rimantadine 14769-73-4,
 Levamisole 36703-88-5, Isoprinosine 36791-04-5,
 Ribavirin 59277-89-3, Acyclovir 79217-60-0,
 Cyclosporin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (combination; isoindole derivative for treatment or prevention of cutaneous lupus)


RN 50-18-0 HCAPLUS

CN 2H-1,3,2-Oxazaphosphorin-2-amine, N,N-bis(2-chloroethyl)tetrahydro-, 2-oxide (CA INDEX NAME)



RN 50-35-1 HCAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- (CA INDEX NAME)



RN 57-92-1 HCAPLUS

CN D-Streptamine, O-2-deoxy-2-(methylamino)- α -L-glucopyranosyl-
(1 \rightarrow 2)-O-5-deoxy-3-C-formyl- α -L-lyxofuranosyl-(1 \rightarrow 4)-
N1,N3-bis(aminoiminomethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 59-05-2 HCAPLUS

CN L-Glutamic acid, N-[4-[[[2,4-diamino-6-
pteridiny]methyl]methylamino]benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 60-54-8 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aS,5aS,6S,12aS)-
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 69-53-4 HCAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,

6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 69-72-7 HCAPLUS

CN Benzoic acid, 2-hydroxy- (CA INDEX NAME)




RN 89-57-6 HCAPLUS

CN Benzoic acid, 5-amino-2-hydroxy- (CA INDEX NAME)



RN 103-90-2 HCAPLUS


CN Acetamide, N-(4-hydroxyphenyl)- (CA INDEX NAME)



RN 114-07-8 HCAPLUS


CN Erythromycin (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 446-86-6 HCAPLUS

CN 9H-Purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]- (CA INDEX NAME)



RN 768-94-5 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decan-1-amine (CA INDEX NAME)



RN 1406-05-9 HCAPLUS

CN Penicillin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 8063-07-8 HCAPLUS

CN Kanamycin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 11111-12-9 HCAPLUS

CN Cephalosporin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 13392-28-4 HCAPLUS


CN Tricyclo[3.3.1.1.3,7]decane-1-methanamine, α -methyl- (CA INDEX NAME)



RN 14769-73-4 HCAPLUS

CN Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (6S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 36703-88-5 HCAPLUS


CN Inosine, compd. with 1-(dimethylamino)-2-propanol 4-(acetylamino)benzoate (1:3:3) (CA INDEX NAME)

CM 1

CRN 58-63-9

CMF C10 H12 N4 O5

Absolute stereochemistry.



CM 2


CRN 61990-51-0

CMF C9 H9 N O3 . C5 H13 N O

CM 3

CRN 556-08-1


CMF C9 H9 N O3



CM 4

CRN 108-16-7


CMF C5 H13 N O



RN 36791-04-5 HCAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 59277-89-3 HCAPLUS

CN 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- (CA INDEX NAME)



RN 79217-60-0 HCAPLUS

CN Cyclosporin (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 915764-31-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(isoindole derivative for treatment or prevention of cutaneous lupus)


RN 915764-31-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 444287-44-9 444287-44-9D, stereoisomers, salts, and solvates 915764-28-2 915764-29-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (isoindole derivative for treatment or prevention of cutaneous lupus)
 RN 444287-44-9 HCAPLUS
 CN Cyclopropanecarboxamide, N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]methyl]- (CA INDEX NAME)




RN 444287-44-9 HCAPLUS
 CN Cyclopropanecarboxamide, N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]methyl]- (CA INDEX NAME)



RN 915764-28-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]methyl]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 915764-29-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]methyl]-, (-)- (CA INDEX NAME)

Rotation (-).



IT 108-31-6, Maleic anhydride, reactions 4023-34-1,
Cyclopropanecarbonyl chloride 14064-21-2
24666-56-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(isoindole derivative for treatment or prevention of cutaneous lupus)

RN 108-31-6 HCAPLUS

CN 2,5-Furandione (CA INDEX NAME)




RN 4023-34-1 HCAPLUS


CN Cyclopropanecarbonyl chloride (CA INDEX NAME)



RN 14064-21-2 HCAPLUS
 CN 2-Furancarboxaldehyde, 2,2-dimethylhydrazone (CA INDEX NAME)




RN 24666-56-6 HCAPLUS
 CN 2,6-Piperidinedione, 3-amino-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 92054-27-8P 444287-40-5P 915764-30-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (isoindole derivative for treatment or prevention of cutaneous lupus)
 RN 92054-27-8 HCAPLUS
 CN 4-Isobenzofurancarboxaldehyde, 1,3-dihydro-1,3-dioxo-,
 4-(2,2-dimethylhydrazone) (CA INDEX NAME)




RN 444287-40-5 HCAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 4-(aminomethyl)-2-(2,6-dioxo-3-piperidinyl)-,
 hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 915764-30-6 HCAPLUS

CN 1H-Isindole-4-carboxaldehyde, 2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-, 4-(2,2-dimethylhydrazone) (CA INDEX NAME)




REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RESULTS FROM SEARCHES IN REGISTRY, CAPLUS, AND USPATFULL

=> d que stat l30
L25 STR



Page 1-A



Page 2-A

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE

L27 6 SEA FILE=REGISTRY SSS FUL L25
L28 1 SEA FILE=HCAPLUS ABB=ON L27
L29 3 SEA FILE=USPATFULL ABB=ON L27
L30 4 DUP REMOV L28 L29 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr l30 1-4

L30 ANSWER 1 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2007:291243 USPATFULL Full-text

TITLE: 7-amido-isindolyl compounds and methods of its use

INVENTOR(S): Man, Hon-Wah, Princeton, NJ, UNITED STATES
 Muller, George W., Bridgewater, NJ, UNITED STATES
 Zhang, Weihong, Highland Park, NJ, UNITED STATES
 PATENT ASSIGNEE(S): Celgene Corporation. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070254942	A1	20071101
APPLICATION INFO.:	US 2007-818927	A1	20070615 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2005-250408, filed on 17 Oct 2005, GRANTED, Pat. No. US 7256210 Division of Ser. No. US 2004-798317, filed on 12 Mar 2004, GRANTED, Pat. No. US 7034052		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-454155P	20030312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1-45	
LINE COUNT:	3431	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention encompasses 7-amido-isindolyl compounds and methods of using these compounds and compositions in mammals for treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 760958-90-5P 760958-99-4P 760959-12-4P
 760959-13-5P 760959-14-6P 760959-15-7P
 (preparation of aminoisindolone derivs. via heterocyclization of aminopropanol derivs. and benzoic acid derivs.)
 RN 760958-90-5 USPATFULL
 CN 2H-Isindole-2-propanamide, N-(acetyloxy)-7-[(cyclopropylcarbonyl)amino]- β -(3-ethoxy-4-methoxyphenyl)-1,3-dihydro-1-oxo-, (β R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 760958-99-4 USPATFULL
 CN 2H-Isindole-2-propanamide, N-(acetyloxy)-4-chloro-7-[(cyclopropylcarbonyl)amino]- β -(3-ethoxy-4-methoxyphenyl)-1,3-dihydro-1-oxo-, (β R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-12-4 USPATFULL

CN Cyclopropanecarboxylic acid, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-13-5 USPATFULL

CN Propanoic acid, 2-methyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-14-6 USPATFULL

CN Propanoic acid, 2,2-dimethyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-15-7 USPATFULL

CN Butanoic acid, 3,3-dimethyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)

Absolute stereochemistry.



L30 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER:

2006:68140 USPATFULL [Full-text](#)

TITLE:

7-Amido-isindolyl compounds and methods of their use

INVENTOR(S):

Man, Hon-Wah, Princeton, NJ, UNITED STATES

Muller, George W., Bridgewater, NJ, UNITED STATES

Zhang, Weihong, Highland Park, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060058362	A1	20060316
	US 7256210	B2	20070814
APPLICATION INFO.:	US 2005-250408	A1	20051017 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2004-798317, filed on 12 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-454155P	20030312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 51 Louisiana Avenue, N.W, WASHINGTON, DC, 20001-2113, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1-45	
LINE COUNT:	3452	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention encompasses 7-amido-isindolyl compounds and methods of using these compounds and compositions in mammals for treatment, prevention or

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

760959-13-5P 760959-14-6P 760959-15-7P


RN 760958-90-5 USPATFULL

Absolute stereochemistry.




CN 2H-Isoindole-2-propanamide, N-(acetyloxy)-4-chloro-7-

Absolute stereochemistry.




Absolute stereochemistry.



RN 760959-13-5 USPATFULL

CN Propanoic acid, 2-methyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-14-6 USPATFULL

CN Propanoic acid, 2,2-dimethyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-15-7 USPATFULL

CN Butanoic acid, 3,3-dimethyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)

Absolute stereochemistry.



L30 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2004:780510 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 141:277486

TITLE: A preparation of 7-aminoisoindolone derivatives
 INVENTOR(S): Man, Hon-Wah; Muller, George W.; Zhang, Weihong
 PATENT ASSIGNEE(S): Celgene Corporation, USA
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080423	A2	20040923	WO 2004-US7743	20040312
WO 2004080423	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004220457	A1	20040923	AU 2004-220457	20040312
CA 2518584	A1	20040923	CA 2004-2518584	20040312
US 20040254214	A1	20041216	US 2004-798317	20040312
US 7034052	B2	20060425		
EP 1605896	A2	20051221	EP 2004-720448	20040312
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
BR 2004008223	A	20060301	BR 2004-8223	20040312
CN 1784382	A	20060607	CN 2004-80012360	20040312
JP 2006519851	T	20060831	JP 2006-507155	20040312
NZ 542671	A	20081224	NZ 2004-542671	20040312
US 20060058362	A1	20060316	US 2005-250408	20051017
US 7256210	B2	20070814		
US 20070254942	A1	20071101	US 2007-818927	20070615
PRIORITY APPLN. INFO.:			US 2003-454155P	P 20030312
			US 2004-798317	A3 20040312
			WO 2004-US7743	W 20040312
			US 2005-250408	A3 20051017
OTHER SOURCE(S):	MARPAT 141:277486			

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of 7-aminoisindole derivs. of formula I [wherein: Y is C(O), CH₂, CH₂C(O), or SO₂; X is H; Z is -alkyl-CO₂H, alkyl, -alkyl-OH, or -alkyl-NH₂, etc.; R₁ and R₂ are independently selected from (cyclo)alkyl or -alkyl-cycloalkyl], useful for treatment, prevention or management of cancer, inflammatory bowel disease, and myelodysplastic syndrome, etc. (no biol. data). For instance, isindole derivative II was prepared via heterocyclization of aminopropanol derivative III and benzoic acid derivative IV with a yield of 64% (example 1).

IT 760958-90-5P 760958-99-4P 760959-12-4P

760959-13-5P 760959-14-6P 760959-15-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminoisindolone derivs. via heterocyclization of aminopropanol derivs. and benzoic acid derivs.)

RN 760958-90-5 HCAPLUS

CN 2H-Isindole-2-propanamide, N-(acetyloxy)-7-[(cyclopropylcarbonyl)amino]-β-(3-ethoxy-4-methoxyphenyl)-1,3-dihydro-1-oxo-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 760958-99-4 HCAPLUS

CN 2H-Isindole-2-propanamide, N-(acetyloxy)-4-chloro-7-[(cyclopropylcarbonyl)amino]-β-(3-ethoxy-4-methoxyphenyl)-1,3-dihydro-1-oxo-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-12-4 HCAPLUS

CN Cyclopropanecarboxylic acid, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-13-5 HCAPLUS

CN Propanoic acid, 2-methyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-14-6 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 760959-15-7 HCAPLUS

CN Butanoic acid, 3,3-dimethyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-

dihydro-1-oxo-2H-isindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:321559 USPATFULL [Full-text](#)
TITLE: 7-Amido-isindolyl compounds and their pharmaceutical uses

INVENTOR(S): Man, Hon-Wah, Princeton, NJ, UNITED STATES
Muller, George W., Bridgewater, NJ, UNITED STATES
Zhang, Weihong, Highland Park, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040254214	A1	20041216
	US 7034052	B2	20060425
APPLICATION INFO.:	US 2004-798317	A1	20040312 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-454155P	20030312 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 51 Louisiana Aveue, N.W, WASHINGTON, DC, 20001-2113	

NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 3628

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention encompasses 7-amido-isindolyl compounds and methods of using these compounds and compositions in mammals for treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 760958-90-5P 760958-99-4P 760959-12-4P
760959-13-5P 760959-14-6P 760959-15-7P
(preparation of aminoisindolone derivs. via heterocyclization of aminopropanol derivs. and benzoic acid derivs.)

RN 760958-90-5 USPATFULL

CN 2H-Isindole-2-propanamide, N-(acetyloxy)-7-[(cyclopropylcarbonyl)amino]- β -(3-ethoxy-4-methoxyphenyl)-1,3-dihydro-1-oxo-, (R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 760958-99-4 USPATFULL

CN 2H-Isoindole-2-propanamide, N-(acetyloxy)-4-chloro-7-
[(cyclopropylcarbonyl)amino]-β-(3-ethoxy-4-methoxyphenyl)-1,3-
dihydro-1-oxo-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-12-4 USPATFULL

CN Cyclopropanecarboxylic acid, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-
dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-
oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-13-5 USPATFULL

CN Propanoic acid, 2-methyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-
dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-
oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-14-6 USPATFULL

CN Propanoic acid, 2,2-dimethyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 760959-15-7 USPATFULL

CN Butanoic acid, 3,3-dimethyl-, [(3R)-3-[7-[(cyclopropylcarbonyl)amino]-1,3-dihydro-1-oxo-2H-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-1-oxopropyl]azanyl ester (CA INDEX NAME)

Absolute stereochemistry.



SEARCH HISTORY

=> d his ful

(FILE 'HOME' ENTERED AT 17:15:16 ON 19 FEB 2009)

FILE 'HCAPLUS' ENTERED AT 17:17:56 ON 19 FEB 2009

E ZELDIS JEROME B/AU
 L1 117 SEA ABB=ON ("ZELDIS J R"/AU OR "ZELDIS JEROME"/AU OR "ZELDIS JEROME B"/AU OR "ZELDIS JEROME BERNARD"/AU OR "ZELDIS JERRY B"/AU)
 E SCHAFAER PETER H/AU
 L2 105 SEA ABB=ON ("SCHAFAER PETER"/AU OR "SCHAFAER PETER H"/AU OR "SCHAFAER PETER H SCHAFAER"/AU OR "SCHAFAER PETER HENRY"/AU)
 L3 6 SEA ABB=ON L1 AND L2
 SELECT RN L3 1-6

FILE 'REGISTRY' ENTERED AT 17:18:37 ON 19 FEB 2009

L4 60 SEA ABB=ON (768-94-5/BI OR 1744-22-5/BI OR 19171-19-8/BI OR 191732-72-6/BI OR 340019-69-4/BI OR 4023-34-1/BI OR 444287-44-9/BI OR 50-35-1/BI OR 58-55-9/BI OR 608141-41-9/BI OR 9001-08-5/BI OR 9001-66-5/BI OR 9012-25-3/BI OR 103-90-2/BI OR 108-24-7/BI OR 108-31-6/BI OR 11111-12-9/BI OR 114-07-8/BI OR 1188-21-2/BI OR 13392-28-4/BI OR 1406-05-9/BI OR 14064-21-2/BI OR 14769-73-4/BI OR 202271-89-4/BI OR 202271-90-7/BI OR 202271-91-8/BI OR 24666-56-6/BI OR 253168-94-4/BI OR 2614-06-4/BI OR 340019-67-2/BI OR 363-24-6/BI OR 36703-88-5/BI OR 36791-04-5/BI OR 39746-25-3/BI OR 444287-40-5/BI OR 446-86-6/BI OR 50-18-0/BI OR 5434-20-8/BI OR 57-92-1/BI OR 59-05-2/BI OR 59277-89-3/BI OR 60-54-8/BI OR 603-11-2/BI OR 608141-43-1/BI OR 6296-53-3/BI OR 635705-76-9/BI OR 69-53-4/BI OR 69-72-7/BI OR 79217-60-0/BI OR 8063-07-8/BI OR 841-67-8/BI OR 874946-00-6/BI OR 89-57-6/BI OR 9036-21-9/BI OR 915764-28-2/BI OR 915764-29-3/BI OR 915764-30-6/BI OR 915764-31-7/BI OR 92054-27-8/BI OR 943225-74-9/BI)

FILE 'HCAPLUS' ENTERED AT 17:18:50 ON 19 FEB 2009

L5 5 SEA ABB=ON L3 AND L4
 L6 2 SEA ABB=ON L5 AND ?CYCLOPROPAN?

FILE 'REGISTRY' ENTERED AT 17:21:47 ON 19 FEB 2009

L7 STRUCTURE 915764-28-2
 L8 STRUCTURE 915764-28-2
 L9 0 SEA SSS SAM L8
 L10 0 SEA SSS FUL L8
 L11 STR L8
 L12 0 SEA SSS SAM L11
 L13 0 SEA SSS FUL L11
 D COST
 L14 STR L11
 L15 0 SEA SSS SAM L14
 L16 0 SEA SSS FUL L14
 L17 STR L14
 L18 0 SEA SSS SAM L17
 L19 0 SEA SSS FUL L17
 L20 STR L17
 L21 0 SEA SSS SAM L20

L22 4 SEA SSS FUL L20
L23 STR L20
L24 2 SEA SSS SAM L23
L25 STR L23
L26 0 SEA SSS SAM L25
L27 6 SEA SSS FUL L25

FILE 'HCAPLUS' ENTERED AT 17:39:23 ON 19 FEB 2009
L28 1 SEA ABB=ON L27

FILE 'USPATFULL' ENTERED AT 17:39:30 ON 19 FEB 2009
L29 3 SEA ABB=ON L27

FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:39:46 ON 19 FEB 2009
L30 4 DUP REMOV L28 L29 (0 DUPLICATES REMOVED)

FILE 'BEILSTEIN' ENTERED AT 17:40:29 ON 19 FEB 2009
L31 0 SEA ABB=ON L27

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2009 VOL 150 ISS 8
FILE LAST UPDATED: 18 Feb 2009 (20090218/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 FEB 2009 HIGHEST RN 1108235-09-1
DICTIONARY FILE UPDATES: 18 FEB 2009 HIGHEST RN 1108235-09-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 19 Feb 2009 (20090219/PD)

FILE LAST UPDATED: 19 Feb 2009 (20090219/ED)

HIGHEST GRANTED PATENT NUMBER: US7493662

HIGHEST APPLICATION PUBLICATION NUMBER: US20090049575

CA INDEXING IS CURRENT THROUGH 19 Feb 2009 (20090219/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 19 Feb 2009 (20090219/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2008

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2008

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

FILE BEILSTEIN

FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.

FILE CONTAINS 10,322,808 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For more detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

>>> Price change as of January 1st, 2008: Connect Time and Structure Search fees re-introduced. See NEWS and HELP COST <<<